{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:53:20Z","timestamp":1789502000748,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13318-020-00660-2","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T05:26:14Z","timestamp":1606195574000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Two Analytical Methods for Busulfan Therapeutic Drug Monitoring"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-8730","authenticated-orcid":false,"given":"Simona","family":"De Gregori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-1978","authenticated-orcid":false,"given":"Carmine","family":"Tinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-3822","authenticated-orcid":false,"given":"Federica","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-7205","authenticated-orcid":false,"given":"Antonella","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"660_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0631-y","author":"B Schiltmeyer","year":"2003","unstructured":"Schiltmeyer B, Klingebiel T, Schwab M, M\u00fbrdter TE, Ritter CA, Jenke A, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol. 2003. https:\/\/doi.org\/10.1007\/s00280-003-0631-y.","journal-title":"Cancer Chemother Pharmacol."},{"key":"660_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702561","author":"HT Tran","year":"2000","unstructured":"Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 2000. https:\/\/doi.org\/10.1038\/sj.bmt.1702561.","journal-title":"Bone Marrow Transplant"},{"key":"660_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701322","author":"US Schuler","year":"1998","unstructured":"Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 1998. https:\/\/doi.org\/10.1038\/sj.bmt.1701322.","journal-title":"Bone Marrow Transplant"},{"key":"660_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.022","author":"IH Bartelink","year":"2009","unstructured":"Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009. https:\/\/doi.org\/10.1016\/j.bbmt.2008.11.022.","journal-title":"Biol Blood Marrow Transplant"},{"key":"660_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006295789","author":"BP Booth","year":"2007","unstructured":"Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007. https:\/\/doi.org\/10.1177\/0091270006295789.","journal-title":"J Clin Pharmacol"},{"key":"660_CR6","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.7.s3.2.x","author":"B Bostrom","year":"2003","unstructured":"Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant. 2003. https:\/\/doi.org\/10.1034\/j.1399-3046.7.s3.2.x.","journal-title":"Pediatr Transplant."},{"key":"660_CR7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01555.x","author":"S Cremers","year":"2002","unstructured":"Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol. 2002. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01555.x.","journal-title":"Br J Clin Pharmacol"},{"key":"660_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704707","author":"J Zwaveling","year":"2005","unstructured":"Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005. https:\/\/doi.org\/10.1038\/sj.bmt.1704707.","journal-title":"Bone Marrow Transplant"},{"key":"660_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000231482.15277.48","author":"J Zwaveling","year":"2006","unstructured":"Zwaveling J, den Hartigh J, Lankester AC, et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs. 2006. https:\/\/doi.org\/10.1097\/01.cad.0000231482.15277.48.","journal-title":"Anticancer Drugs"},{"key":"660_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.143","author":"M Ansari","year":"2010","unstructured":"Ansari M, Lauzon-Joset JF, Vachon MF, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010. https:\/\/doi.org\/10.1038\/bmt.2009.143.","journal-title":"Bone Marrow Transplant"},{"key":"660_CR11","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.135","author":"M Ansari","year":"2009","unstructured":"Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics. 2009. https:\/\/doi.org\/10.2217\/pgs.09.135.","journal-title":"Pharmacogenomics"},{"key":"660_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700994","author":"P Ljungman","year":"1997","unstructured":"Ljungman P, Hassan M, B\u00e9k\u00e1ssy AN, Ringd\u00e9n O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997. https:\/\/doi.org\/10.1038\/sj.bmt.1700994.","journal-title":"Bone Marrow Transplant"},{"key":"660_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.006","author":"JH Zao","year":"2015","unstructured":"Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, et al. Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant. 2015. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.006.","journal-title":"Biol Blood Marrow Transplant"},{"key":"660_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000468","author":"E Choong","year":"2018","unstructured":"Choong E, Uppugunduri CRS, Marino D, Kuntzinger M, Doffey-Lazeyras F, Lo Piccolo R, et al. Therapeutic drug monitoring of B#busulfan for the management of pediatric patients: cross-validation of methods and long-term performance. Ther Drug Monit. 2018. https:\/\/doi.org\/10.1097\/FTD.0000000000000468.","journal-title":"Ther Drug Monit"},{"key":"660_CR15","unstructured":"Guideline on Bioanalytical Method Validation (2011) (EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2). The European Agency for the Evaluation of Medicinal Products (EMEA), pp 1\u201323"},{"key":"660_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2002.01020.x","author":"HX Barnhart","year":"2002","unstructured":"Barnhart HX, Haber M, Song J. Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics. 2002. https:\/\/doi.org\/10.1111\/j.0006-341x.2002.01020.x.","journal-title":"Biometrics"},{"key":"660_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.theriogenology.2010.01.003","author":"PF Watson","year":"2010","unstructured":"Watson PF, Petrie A. Method agreement analysis: a review of correct methodology. Theriogenology. 2010. https:\/\/doi.org\/10.1016\/j.theriogenology.2010.01.003.","journal-title":"Theriogenology"},{"key":"660_CR18","doi-asserted-by":"publisher","unstructured":"Giavarina D. Understanding bland Altman analysis. Biochem Med (Zagreb). 2015. https:\/\/doi.org\/10.11613\/BM.2015.015.","DOI":"10.11613\/BM.2015.015"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00660-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-020-00660-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00660-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T17:06:42Z","timestamp":1610903202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-020-00660-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s13318-020-00660-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"24 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors received no specific funding for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors Simona De Gregori, Antonella Bartoli, Carmine Tinelli and Federica Manzoni declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study did not require any specific ethics approval. The Fondazione IRCCS Policlinico San Matteo is a health and research institute: the patients or their relatives provided written informed consent for the processing of personal data, as well as for research purpose. The Bioethics Committee of Fondazione verified the correct data collection in the informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Informed Consent"}},{"value":"I, Simona De Gregori, on behalf of any co-authors, hereby declare that we all participated in the study and in the development of the manuscript titled \u201cComparison of two analytical methods for Busulfan therapeutic drug monitoring\u201d. We have read the final version and give our consent for the article to be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"A.B. and S.DG. conceived the presented idea, and planned and carried out the experiments. C.T. and F.M. processed the experimental data, designed the figures and aided in interpreting the results. A.B., S.DG., C.T. and F.M. contributed to the writing of the manuscript. All the authors have accepted responsibility for the entire content of this manuscript and approved submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All data and results are stored in the laboratories\u2019 database by the Fondazione IRCCS Policlinico San Matteo.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}